Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

biotuesdays.com image

News from biotuesdays.com

biotuesdays.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is biotuesdays.com credible or reliable? Our Factuality score answers both of those questions. When it comes to biotuesdays.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about biotuesdays.com

Where is biotuesdays.com located?biotuesdays.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biotuesdays.com News

AC Immune says Parkinson's drug slows progression

Parkinson's Disease · Lausanne

AC Immune says Parkinson's drug slows progression

100% Center coverage: 2 sources

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.See the Story

HeartBeam Secures FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal – Citybuzz

United States · United States

HeartBeam Secures FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal – Citybuzz

HeartBeam Inc. (NASDAQ: BEAT) has received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment following a successful appeal of a prior not substantially equivalent (NSE) determination. The clearance represents a significant regulatory milestone for the medical technology company, which focuses on transforming cardiac care through personalized insights. The company’s patented cable-free technology captures cardi…See the Story

Cadrenal Therapeutics (NASDAQ: CVKD) Adds HIT, Factor XIa Drugs in Quiet Expansion

Cadrenal Therapeutics (NASDAQ: CVKD) Adds HIT, Factor XIa Drugs in Quiet Expansion

Cadrenal Therapeutics broadens its anticoagulation platform with tecarfarin, a Factor XIa program and Phase 2 VLX-1005 for HIT, setting up new trial catalysts.See the Story

Breaking News Topics Related to biotuesdays.com